Cargando…

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors

Mutant-specific inhibitors of KRAS(G12C), such as AMG510 (sotorasib) and MRTX849 (adagrasib), offer the unprecedented opportunity to inhibit KRAS, the most frequently mutated and heretofore undruggable oncoprotein. While clinical data are still limited, on-target mutations in KRAS(G12C) at position...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Siyu, Callow, Marinella G., Fortin, Jean-Philippe, Khan, Zia, Bray, David, Costa, Mike, Shi, Zhen, Wang, Weiru, Evangelista, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170150/ https://www.ncbi.nlm.nih.gov/pubmed/35471904 http://dx.doi.org/10.1073/pnas.2120512119

Ejemplares similares

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility
por: Chen, Chih-Chieh, et al.
Publicado: (2020)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

Searching for treatments for non-G12C-KRAS mutant cancers
por: Guo, Christina, et al.
Publicado: (2021)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine–dependent interface: a model for KRAS oligomerization
por: Lee, Ki-Young, et al.
Publicado: (2021)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS(G12C) Inhibitor
por: Bröker, Joachim, et al.
Publicado: (2022)

Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS(G12D) mutated pancreatic cancer in vivo model
por: Panebianco, Concetta, et al.
Publicado: (2023)

Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017)

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
por: Stites, Edward C., et al.
Publicado: (2018)

Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)

NUDT7 Loss Promotes Kras(G12D) CRC Development
por: Song, Jinsoo, et al.
Publicado: (2020)

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
por: Tsai, Yihsuan S., et al.
Publicado: (2022)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
por: Huynh, Minh V., et al.
Publicado: (2022)

Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
por: Wright, Katharine M., et al.
Publicado: (2023)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mce5rskdu7ar9pti66qr10vv25